Home-Hero-4-no-button
Mobile-Hero-4-no-button

MERZ ANNOUNCES THE COMMERCIAL LAUNCH OF THE CELLFINA® SYSTEM IN EUROPE

Frankfurt am Main, Germany - September 14, 2017 Merz today announced the commercial availability of the Cellfina® System in select European markets. The Cellfina® System is currently the only EU CE-Marked and U.S. FDA-cleared minimally-invasive procedure that treats the underlying structural cause of cellulite with results that last at least three years. Cellfina® is intended for long-term reduction of cellulite by precise release of targeted structural tissue (fibrous septae).

 

View Press Release

THE CELLFINA® SYSTEM RECOGNIZED BY REALSELF AS MOST WORTH IT AWARD WINNER

Raleigh, N.C., USA – June 5, 2017 – Merz Aesthetics, a division of Merz Pharma Group, announced today that the Cellfina® System has been named a 2016 RealSelf Most Worth It award winner in the “Cellulite Treatment” category.

 

View Press Release

MERZ AESTHETICS ANNOUNCES THREE YEAR FDA CLEARANCE FOR CELLFINA® SYSTEM

RALEIGH, N.C. – OCTOBER 17, 2016 – Merz Aesthetics, a division of Merz North America (U.S. affiliate of the global Merz Pharma Group), announced today that the U.S. Food and Drug Administration (FDA) has cleared its Cellfina® System for the long-term improvement in the appearance of cellulite on the buttocks and thighs of adult females with no loss of benefit for up to 3 years.

 

View Press Release

MERZ ANNOUNCES CE CLEARANCE OF THE CELLFINA® SYSTEM  FOR THE LONG-TERM REDUCTION OF CELLULITE

FRANKFURT, GERMANY – JULY 14, 2016 – Merz Pharma Group today announced CE Mark clearance of the Cellfina® System, signifying its conformity with all EU regulations. Cellfina® is intended for long-term reduction of cellulite in the buttocks and thighs by precise release of targeted structural tissue (fibrous septae). Results of treatment with Cellfina® are expected to last up to two years. Cellfina® is currently available in the U.S. and has the longest duration of results as cleared by the U.S. Food and Drug Administration (FDA).

 

View Press Release